MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

PONV

  • Home
  • PONV
Wearable TEAS Outperforms Metoclopramide in Managing Moderate to Severe Postoperative Nausea and Vomiting
Posted inAnesthesiology General Surgery news

Wearable TEAS Outperforms Metoclopramide in Managing Moderate to Severe Postoperative Nausea and Vomiting

Posted by By MedXY 03/23/2026
A randomized clinical trial demonstrates that wearable Transcutaneous Electrical Acupoint Stimulation (TEAS) provides superior 2-hour remission and significantly lower 24-hour relapse rates compared to intravenous metoclopramide for moderate to severe PONV in high-risk surgical patients.
Read More
Wearable TEAS Device Outperforms Metoclopramide for Moderate to Severe Postoperative Nausea and Vomiting
Posted inAnesthesiology General Surgery news

Wearable TEAS Device Outperforms Metoclopramide for Moderate to Severe Postoperative Nausea and Vomiting

Posted by By MedXY 01/31/2026
A randomized clinical trial demonstrates that wearable transcutaneous electrical acupoint stimulation (TEAS) provides superior symptom relief and significantly lower relapse rates compared to intravenous metoclopramide in managing moderate to severe postoperative nausea and vomiting.
Read More
  • Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies
  • Evolving GVHD Prophylaxis in AlloHSCT: Insights from a Large Real-World Spanish Cohort
  • Unraveling the Risks: T-Cell Lymphoma After CAR T-Cell Therapy—A Rare but Real Concern
  • Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma
  • Enhancing Bone Marrow Fibrosis Diagnosis: Clinical Evaluation of AI-Driven Continuous Indexing of Fibrosis (CIF)
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top